The GLP-1 news channel weighs Lilly's push against grey-market peptide sellers and what that fight could mean for the future of these drugs.
Recap by typeshit. Full story at On The Pen™ GLP-1 News.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short clip of Rosie O'Donnell discussing the tirzepatide drug Mounjaro. Few details are given beyond the title.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
A short fitness clip from an Equinox ambassador on why weight loss from Ozempic is not the same as gaining muscle.
The top result came from a confined 400 mg cohort over four weeks, though Biomea says placebo weight loss muddies it. The company now wants a partner to fund phase II.
Loading…